Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Breast Cancer: Current Trends and Future Challenges in Evaluation and...
share announcement

Breast Cancer: Current Trends and Future Challenges in Evaluation and Treatment

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 2942

Special Issue Editors

Dr. Stefano Spinaci

E-Mail Website
Guest Editor
Breast Unit, Department of Surgery, Ospedale Villa Scassi ASL3, 16149 Genova, Italy
Interests: surgery; breast surgery; breast unit; breast cancer; breast imaging; oncology therapy
Dr. Giulia Ferrarazzo

E-Mail
Guest Editor
Nuclear Medicine, Ospedale Villa Scassi ASL3, 16149 Genova, Italy
Interests: medical imaging; nuclear medicine; molecular imaging; PET; SPECT; radionuclide imaging; breast cancer

Special Issue Information

Dear Colleagues,

In recent years, the treatment of breast cancer has developed significantly, focusing on conservative surgical strategies, robotic-assisted surgery, and male breast cancer evaluation as well as care.

Conservative surgery aims to remove tumors while preserving as much healthy breast tissue as possible. In breast cancer procedures, robotic surgery is increasingly employed; it offers the possibility of enhanced precision and minimally invasive techniques, making small incisions and scarring, reducing recovery time, and, finally, improving the comfort and outcomes of patients. Male breast cancer presents many challenges. Because of its rarity, awareness and education about this male cancer are essential to ensure early detection as well as diagnosis and appropriate treatment.

This Special Issue aims to summarize the most promising clinical and technical applications/improvements in breast conservative surgery and robotic techniques. The importance of early diagnoses and tailored treatments in male breast cancer will also be underlined.

In this Special Issue we will insert original articles, case reports, and reviews focusing on conservative strategies and robotic techniques in breast cancer surgery, as well as novel insights into male breast cancer.

Dr. Stefano Spinaci
Dr. Giulia Ferrarazzo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • breast surgery
  • conservative surgery
  • robotic breast techniques
  • male breast cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 1129 KiB  
Article
Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05)
by Jin Hee Kim, Sang Jun Byun, Myeongsoo Kim, Kyung Hwan Shin, Dong Yun Kim, Han Byoel Lee, Tae Hyun Kim, Yeon Joo Kim, Yong Bae Kim, Jee Suk Chang, Kyubo Kim and Sun Young Lee
J. Pers. Med. 2024, 14(9), 941; https://doi.org/10.3390/jpm14090941 - 4 Sep 2024
Viewed by 1272
Abstract
Background: We designed a multi-institutional retrospective study to investigate the previously unreported failure pattern, survivals, and prognostic factors after postoperative radiotherapy (PORT) in triple negative breast cancer (TNBC) patients in South Korea. Materials and Methods: We retrospectively reviewed 699 patients with TNBC who [...] Read more.
Background: We designed a multi-institutional retrospective study to investigate the previously unreported failure pattern, survivals, and prognostic factors after postoperative radiotherapy (PORT) in triple negative breast cancer (TNBC) patients in South Korea. Materials and Methods: We retrospectively reviewed 699 patients with TNBC who underwent PORT at six institutions between 2008 and 2010. The median follow-up period was 94 months (range: 7–192 months). There were 216, 380, and 100 patients in stages I, II, and III, respectively. Results: After 94 months post-treatment, all patients with pathologic complete remission after neoadjuvant chemotherapy were alive without any failure. Distant metastasis was the main cause of failure. The 5-year overall survival rate was 91.4%, 5-year loco-regional relapse-free survival rate (LRRFS) was 92.3%, 5-year distant metastasis-free survival rate (DMFS) was 89.4%, and 5-year disease-free survival rate (DFS) was 85.2%. On multivariate (Cox) analysis, T and N stages were significant prognostic factors for survival, and lympho-vascular invasion (LVI) was a significant factor for LRRFS and DMFS. Ki-67 expression was significantly associated with LRRFS and DFS. Conclusion: We verified that T and N stages, LVI, and Ki-67 expression were significantly associated with survival outcomes after PORT in TNBC. Full article
(This article belongs to the Special Issue Breast Cancer: Current Trends and Future Challenges in Evaluation and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

33 pages, 718 KiB  
Review
Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review
by Menelaos Zafrakas, Ioannis Gavalas, Panayiota Papasozomenou, Christos Emmanouilides and Maria Chatzidimitriou
J. Pers. Med. 2025, 15(5), 177; https://doi.org/10.3390/jpm15050177 - 27 Apr 2025
Abstract
Objectives: The aim of this scoping review was to delineate the current role and possible applications of proteomics in personalized breast cancer diagnostic evaluation and treatment. Methods: A comprehensive search in PubMed/MEDLINE and Scopus/EMBASE was conducted, according to the PRISMA–ScR guidelines. Inclusion criteria: [...] Read more.
Objectives: The aim of this scoping review was to delineate the current role and possible applications of proteomics in personalized breast cancer diagnostic evaluation and treatment. Methods: A comprehensive search in PubMed/MEDLINE and Scopus/EMBASE was conducted, according to the PRISMA–ScR guidelines. Inclusion criteria: proteomic studies of specimens from breast cancer patients, clinically relevant studies and clinical studies. Exclusion criteria: in silico, in vitro and studies in animal models, review articles, case reports, case series, comments, editorials, and articles in language other than English. The study protocol was registered in the Open Science Framework. Results: In total, 1093 records were identified, 170 papers were retrieved and 140 studies were selected for data extraction. Data analysis and synthesis of evidence showed that most proteomic analyses were conducted in breast tumor specimens (n = 77), followed by blood samples (n = 48), and less frequently in other biologic material taken from breast cancer patients (n = 19). The most commonly used methods were liquid chromatography–tandem mass spectrometry (LC–MS/MS), followed by Matrix-assisted laser desorption/ionization-time of flight (MALDI–TOF), Surface-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI–TOF) and Reverse Phase Protein Arrays (RPPA). Conclusions: The present review provides a thorough map of the published literature reporting clinically relevant results yielded from proteomic studies in various biological samples from different subgroups of breast cancer patients. This analysis shows that, although proteomic methods are not currently used in everyday practice to guide clinical decision-making, nevertheless numerous proteins identified by proteomics could be used as biomarkers for personalized diagnostic evaluation and treatment of breast cancer patients. Full article
(This article belongs to the Special Issue Breast Cancer: Current Trends and Future Challenges in Evaluation and Treatment)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

13 pages, 535 KiB  
Systematic Review
Treatments of Interest in Male Breast Cancer: An Umbrella Review
by Stefano Spinaci, Luca Arecco, Agnese Anedda, Lucia Martino, Emma Firpo, Matteo Ghilli, Matteo Lambertini and Giulia Ferrarazzo
J. Pers. Med. 2025, 15(2), 66; https://doi.org/10.3390/jpm15020066 - 11 Feb 2025
Viewed by 803
Abstract
Background: Male breast cancer (MaBC) is a rare disease and due to its rarity and the lack of specific protocols for its management, treatment algorithms are extrapolated from female breast cancer (FBC). To optimize MaBC treatment, we conceived an umbrella review with the [...] Read more.
Background: Male breast cancer (MaBC) is a rare disease and due to its rarity and the lack of specific protocols for its management, treatment algorithms are extrapolated from female breast cancer (FBC). To optimize MaBC treatment, we conceived an umbrella review with the aim of supplying an evidence-based summary of systematic reviews published about this topic in the last twenty years. Methods: This umbrella review was performed according to a predefined protocol (PROSPERO number CRD42024574299). We performed a literature search of the PubMed and Cochrane Libraries databases and we considered systematic reviews on MaBC treatment published from 2004 to 2024. We evaluated relevant treatments in the management of MaBC, including surgery, radiotherapy, and systemic treatments. We conducted the quality assessment according to A MeaSurement Tool to Assess systematic Reviews version 2 (AMSTAR-2), and the description of the main findings of eligible articles. Results: Seven systematic reviews were selected and the main findings were compiled. Breast-conserving surgery is a reasonable treatment approach and, in selected cases, equivalent in terms of safety and survival outcomes compared to mastectomy. Sentinel lymph node biopsy represents a successful surgical practice with similar accuracy compared to female cases. Adjuvant radiotherapy improves overall survival in MaBC patients following partial mastectomy and after radical mastectomy, in case of involved nodes. Finally, Tamoxifen is associated with an improvement of survival outcomes; aromatase inhibitor and gonadotrophin-releasing hormone should be used only in case of contraindications to tamoxifen. Conclusions: Further research and improved guidelines for MaBC treatment should consider these evidence-based data. Full article
(This article belongs to the Special Issue Breast Cancer: Current Trends and Future Challenges in Evaluation and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop